| Product Unit Size | Cost | Quantity | Stock |
|---|
SAR245409 is a pyridopyrimidinone derivative that inhibits PI3K and mTOR. This compound exhibits anticancer chemotherapeutic activity and shows benefit in clinical trials as a potential treatment for advanced solid tumors. SAR245409 inhibits cell proliferation and tumor growth in a variety of cancer models.
| Cas No. | 1349796-36-6, 1123889-87-1 |
|---|---|
| Purity | ≥96% |
| Formula | C31H29N5O6S |
| Formula Wt. | 599.66 |
| Chemical Name | N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide |
| IUPAC Name | N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide |
| Synonym | XL765, Voxtalisib, SAR245409; XL-765; PI3K-IN-1; Voxtalisib analog |
| Solubility | DMSO 54 mg/mL (199.78 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Off white to light yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Yu P, Laird AD, Du X, et al. Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Impacting the PI3K Pathway. Mol Cancer Ther. 2014 Mar 19. [Epub ahead of print]. PMID: 24634413.
Papadopoulos K, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014 Feb 28. [Epub ahead of print]. PMID: 24583798.